Photo: First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

  • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
  • Takeda’s manufacturing site at Lessines, Belgium, is contributing to the production of the clinical material for the NIH Phase 3 trial, emphasizing the importance of Belgium as a pharmaceutical hub.

Read the rest of this article in our digital newsletter


ニュース一覧

新着ニュース


スポンサー会員

AGC GLASS EUROPE
DAIKIN EUROPE
DELOITTE
GROUP S
H. DE BEUKELAER & CO.
HONDA MOTOR EUROPE LOGISTICS NV
LINKLATERS LLP
NIPPON GASES
SUMITOMO BENELUX
TAKEDA BELGIUM
TOKAI OPTECS
TOSHIBA GLOBAL COMMERCE SOLUTIONS (BENELUX)
TOYOTA MOTOR EUROPE
UMICORE
WILMERHALE (WILMER CUTLER PICKERING HALE AND DORR LLP)